Table 1.
Data about patients enrolled in this study
| Characteristics | Patients, n (%) |
| Sex | |
| Male | 59 (65.6) |
| Female | 31 (34.4) |
| Age (yr) | |
| Median | 53 |
| Range | 23-75 |
| Tumor site | |
| Colon | 39 (43.3) |
| Rectal | 51 (56.7) |
| Combined chemotherapy | |
| Irinotecan-based | 58 (64.4) |
| Oxaliplatin-based | 29 (32.2) |
| Monotherapy | 3 (3.3) |
| Cetuximab use | |
| First line | 29 (32.2) |
| Second line | 23 (25.6) |
| Third line | 28 (31.1) |
| Fourth line or more | 10 (11.1) |
| Response status | |
| Complete response | 3 (3.3) |
| Partial response | 31 (34.4) |
| Stable disease | 35 (38.9) |
| Progressive disease | 21 (23.3) |